• 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
• Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
• Interim data analysis planned at 144 events (deaths) could provide full approval and marketing authorization
• Pivotal Phase 3 study patient enrollment completion is expected in mid-2025
• No serious adverse events related to Bria-IMT™ have been reported to date

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ('BriaCell” or the 'Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today provides a clinical engagement update of its pivotal Phase 3 study of Bria-IMT™ in combination with immune check point inhibitor in metastatic breast cancer (MBC). The study will enroll up to 354 patients randomized 1:1 to the BriaCell combination regimen or physician's choice and will include a small number (n=50) of patients randomized to Bria-IMT™ monotherapy.